2 Clinical Cases
2009-11-11 - English

1) To be able to reflect on the epidemiology of late presentation of HIV disease.
2) To recognise that late presentation may be the result of missed opportunities to diagnose HIV infection.
3) To understand the consequences of late presentation in relation to increased...(more)

HIV Testing and Late Diagnosis
2009-11-11 - English

Introduction to EACS/IAS Special Sessions on Harm Reduction / E. Europe
2009-11-11 - English

2 Clinical Cases 1. Patient with Adherence Issues to ARVs 2. Patient with Short Term Tolerability Issues
2009-11-11 - English

The Role of the Nurse in the Care and Management of Patients with HIV
2009-11-11 - English

2 Clinical Cases
2009-11-11 - English

What and When to Start
2009-11-11 - English

2 Clinical Cases
2009-11-11 - English

To prompt discussions on the above issues, and raise points that will be covered in the following talk by Dr Fisher

Short Term Toxicity
2009-11-11 - English

Long Term Toxicity
2009-11-11 - English

the long term toxicities of HAART with special focus on hepatic, renal and cardiovascular side effects. Moreover recent data on the development of lipodystrophy will be discussed. The presentation will also provide some insight into the different toxicity profiles of...(more)

2 Clinical Cases
2009-11-11 - English

The History and Future of Basic Science in HIV
2009-11-11 - English

Earlier Recognition of HIV: A Pressing Need
2009-11-11 - English

The negative public health aspects of late presentation of HIV will be reviewed, as well be ongoing initiatives aimed at reducing this.

Award for Excellence in HIV
2009-11-12 - English

Management of HIV Disease: Trends and Future Prospects
2009-11-12 - English

1) The increasing burden of non-AIDS-associated morbidities commonly associated with aging in HIV-infected individuals receiving suppressive antiretroviral therapy.

2) The potential roles of persistent inflammation and immunosenescence in driving these morbidities.

3)...(more)

Scaling up HAART Coverage to Curb HIV and AIDS in Injecting Drug Users
2009-11-12 - English

Efficacy of tenofovir plus emtricitabine compared to emtricitabine based HAART in HIV/HBV coinfected antiretroviral naï individuals in Thailand: a randomized controlled trial
2009-11-12 - English

Frequent detection of multiple, oncogene expressing high risk HPV types in anal swabs from HIV-infected individuals: predictors and association with anal dysplasia
2009-11-12 - English

Characteristics of non-AIDS defining malignancies in the HAART era: a clinico-epidemiological study
2009-11-12 - English

Advancing Harm Reduction in Europe . What has Worked ?
2009-11-12 - English

Has the uptake of treatment for chronic hepatitis C virus infection (CHC) in HIV-positive patients in Europe changed over time?
2009-11-12 - English

Survival and prognostic factors associated with non-AIDS defining malignancies (NADM)
2009-11-12 - English

2 year risk of dying were 36% for viral, 40% for epithelial, 49% for other malignancies. Smoking more than doubled the risk of dying. Only factor reducing the risk was CD4 cell count (per doubling HR:0,66 95%CI:0,55-0,78)

Consequences of International Drug Policy for Injecting Drug Users and the HIV Epidemic in Eastern Europe
2009-11-12 - English

Rapid virological response (RVR) during treatment of acute HCV infection (AHC) in HIV-positive individuals . is it worth it?
2009-11-12 - English

Highly active antiretroviral therapy regimens on the prevalence of anal human papillomavirus infection and anal pathology in HIV-infected men
2009-11-12 - English

Hepatitis delta in HIV-1 infected Romanian adolescents
2009-11-12 - English

Category: 13.3 Other Hepatitis
Title: HEPATITIS DELTA IN HIV-1 INFECTED ROMANIAN ADOLESCENTS
Author(s): C. Oprea1, R. Radoi1, E. Ungureanu1, G. Tardei1, L. Ene1, R. Erhan1, S. Tetradov1, C. Ionescu1, D. Otelea2, E. Ceausu1, D. Duiculescu1
Institute(s): 1V Babes Hospital...(more)

Possible role of chemokine co-receptors in human polyoma virus (HPOV) cell internalization in HIV-infected patients
2009-11-12 - English

Prevalence of primary drug resistance in hepatitis B virus in newly diagnosed HIV patients with chronic hepatitis B in Spain: a national cohort
2009-11-12 - English

Progressive multifocal leukoencephalopathy (PML) in AIDS patients receiving potent antiretroviral therapies: changes in clinical presentation, diagnosis, and prognosis
2009-11-12 - English

INCIDENCE AND EPIDEMIOLOGY OF PML IN HIV PATIENTS

CLINICAL COURSE AND SURVIVAL OF PML DIAGNOSED HIV-INFECTED PATIENTS

CHANGES IN PRESENTATION AND OUTCOME WITH THE USE OF HAART

The ARUD Zurich (Association for Risk Reduction in Drug) Model
2009-11-12 - English

Treatment of HIV-associated lymphoma in the era of highly active antiretroviral therapy . results of the German HIV Lymphoma cohort
2009-11-12 - English

Epidemiology of HIV/STI in the border region Vienna/Austria: results of the BORDERNET sentinel surveillance
2009-11-12 - English

Antiretroviral prophylaxis following sexual exposure to HIV in Italy
2009-11-12 - English

Cost-effectiveness of pre-exposure prophylaxis for HIV in a MSM population
2009-11-12 - English

Non-nucleoside analogs use with rifapicin in HIV-infected patients with tuberculosis
2009-11-12 - English

The long-term safety of vicriviroc
2009-11-12 - English

The long-term safety of vicriviroc, a CCR5 antagonist with longer duration of human exposure than others of the same class.

Non-inferior efficacy shown across different efficacy endpoints in the MONET trial of darunavir/ritonavir (DRV/r) monotherapy
2009-11-12 - English

- Darunavir/r monotherapy vs triple therapy
- Non-inferiority trial and sensitivity analysis
- Downstream consequences of PI-monotherapy failure

Mini Lecture: Mental Illness in the Era of Successful HIV Treament
2009-11-12 - English

The main issues related to the psychiatric aspects of HIV infection. The participants should also be aware of the high prevalence of psychiatric comorbidity in HIV infection. They should see the need for a continuous training in diagnosing and treating psychiatric simptoms in HIV infected patients.

Use of twice daily darunavir as a substitution for dual boosted PIs in virologically suppressed patients: primary endpoint results of a pilot randomized clinical trial
2009-11-12 - English

The outcome of using darunavir in lieu of a suppressive double boosted PI regimen in HIV patients.

Do doctors take neuropsychiatric disorders into account at the time of starting treatment with a non-nucleotide reverse transcriptase inhibitor? The Psiconev study
2009-11-12 - English

Improvements in all-cause mortality across Europe 2002-2007 and regional differences in incidence of HIV/AIDS and non-HIV/AIDS deaths across Europe
2009-11-12 - English

Efficacy and safety of lopinavir/ritonavir monotherapy vs. standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1
2009-11-12 - English

Mortality rates of elderly HIV-infected adult treated with antiretroviral are closer to general population than in younger patients
2009-11-12 - English

A phase II, open-label trial in treatment-naï, HIV-1 infected subjects who received DRV/RTV as induction monotherapy
2009-11-12 - English

Mortality due to cancer in HIV-infected patients compared to the Italian general population
2009-11-12 - English

Once daily single agent therapy with LPV(r) in subjects virologically suppressed on twice daily LPV(r) single agent therapy . IMANI III 48 week final results
2009-11-12 - English

Effect of alendronate on HIV related osteoporosis: a randomised, double-blind, placebo-controlled trial (ANRS 120)
2009-11-12 - English

Risk of specific AIDS and non-AIDS defining cancers according to immunodeficiency, viral replication and antiretroviral therapy in HIV infected patients enrolled in the FHDH-ANRS CO4
2009-11-12 - English

Objective. The relative role of immunodeficiency, viral replication, antiretroviral therapy (cART) on the risk of AIDS-defining (ADC) and non-AIDS defining (NADC) cancers has not been largely explored by specific type of malignancies.
Methods. 52,278 patients who were...(more)

Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY study
2009-11-12 - English

Continuing decline in incidence of central nervous system (CNS) events in the combination antiretroviral therapy (cART) era
2009-11-12 - English

Initiating antiretroviral therapy in HIV-infected subjects with CD4 between 350-500 from EACS. A journay from the guidelines to economic reality
2009-11-12 - English

Urinary albumin and retinol-binding protein as markers of glomerular and tubular dysfunction in HIV infected patients
2009-11-12 - English

Estimating AIDS and non-AIDS related deaths for patients with missing death data
2009-11-12 - English

Mini Lecture: Pros and Cons of Boosted PI Monotherapy
2009-11-12 - English

Interruption of ART for more than 6 months results in poorer CD4 T-cell recovery and significantly more clinical events in the Swiss HIV Cohort Study
2009-11-12 - English

Diabetes incidence and risk factors over 9-year follow-up after first PI initiation in the ANRS C08 APROCO-COPILOTE cohort
2009-11-12 - English

Antiretrovirals
2009-11-13 - English

Risk factors of immune reconstitution inflammatory syndrome (IRIS) after HAART in HIV-infected patients at Chiang Mai University Hospital
2009-11-13 - English

Sequential pregnancies in HIV infected women
2009-11-13 - English

Comorbidity
2009-11-13 - English

Present the updated EACS guidelines on best approach to prevent and treat co-morbidities seen in HIV. The guidelines have been updated and expanded compared to the 2008 edition. The updates relates to virtually all types of co-morbidities, but most importantly are revisions...(more)

CD4 count, viral suppression, prophylaxis and the risk of primary pneumocystis pneumonia in the cART era . the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
2009-11-13 - English

Use of PCR tests to rule out HIV infection in infants born to HIV-infected mothers in Russia: impact on time to diagnosis and health policy
2009-11-13 - English

CD4 count, viral suppression, prophylaxis and the risk of recurrent pneumocystis pneumonia in the cART era . the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
2009-11-13 - English

Lipid alterations in HIV infected adolescents
2009-11-13 - English

Hepatitis Viruses
2009-11-13 - English

Health care index (HCI) and outcome following a diagnosis of tuberculosis (TB)
2009-11-13 - English

Psychosocial aspects in a cohort of vertically infected adolescents. Disclosure, adherence and behavioural profiles
2009-11-13 - English

Randomized, prospective, open-label study to compare the efficacy of treatment with benzathine penicillin or ceftriaxone in early syphilis in HIV infected patients
2009-11-13 - English

Mini Lecture: How to Estimate the Size of the Infected Population that is Unaware of their HIV-Infection Status
2009-11-13 - English

Moving from risk factor assessment to atherosclerosis imaging to select the most appropriate patient for primary prevention
2009-11-13 - English

Hypertension (HTN) and isolated office hypertension (IOH) in HIV-infected patients determined by ambulatory blood pressure monitoring (ABPM): prevalence and risk factors
2009-11-13 - English

Controlling the HIV epidemic in the Netherlands
2009-11-13 - English

Effect of a nutritional intervention on CD4+ T cell decline in HIV-1 positive adults not on antiretroviral therapy: a multicentre randomized controlled double-blind clinical trial (BITE), with 52 weeks of follow-up
2009-11-13 - English

Long term evolution of a cohort of HIV infected patients older than 60 years (COREVIH-IDF-Ouest, France)
2009-11-13 - English

Proportion and trend over calendar time of patients with a low CD4 count or AIDS diagnosis at the time of their first contact with clinical care in Italy
2009-11-13 - English

To evaluate the frequency of patients presenting late to care within the Icona Foundation Study cohort and toe valuate their long term risk of death

Efficacy of nevirapine combined with tenofovir-emtricitabine as initial treatment for HIV-1 infection
2009-11-13 - English

Time to virologic response (TVR) is not associated with response durability in treatment-naïve patients receiving efavirenz (EFV)-based highly active antiretroviral therapy (HAART)
2009-11-13 - English

Viral load outcome after virologic failure of the three original antiretroviral drug classes in 2000-2007
2009-11-13 - English

Correlation between Trofile® test and virological response to a short-term maraviroc exposure in HIV-infected patients
2009-11-13 - English

1) Trofile limitations
2) HIV tropism and its clinical relevance
3) Clinical approach to check CCR5-antagonists efficacy

Mini Lecture: Management of Low Level Viraemia
2009-11-13 - English

Feedback from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV: Mini Lecture: Clinical News
2009-11-13 - English

Mini Lecture: Polypharmacy in Ageing Patients with HIV
2009-11-13 - English

Abdominal adiposity remains highly prevalent in French HIV-infected patients having initiated antiretroviral therapy after 2005
2009-11-13 - English

Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL
2009-11-13 - English

Impact of traditional cardiovascular risk factors and HIV parameters on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4
2009-11-13 - English

Genotypic prediction of HIV-1 tropism: correlation with the virological response to maraviroc and genotypic evolution on maraviroc therapy in the genotropism study
2009-11-13 - English

Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naï HIV-1 infected patients: ARTEN study week 48 results
2009-11-13 - English

lipid changes in naive pts receiving a regimen of TDF/FTC/NVP or TDF/FTC/ATV/r.

Fatty liver disease associated with hepatitis C and/or human immunodeficiency virus: characterization of the link between hepatic steatosis, insulin resistance and metabolic syndrome
2009-11-13 - English

Comparison of the use of last genotype versus all past genotypes to classify patients according to resistance algorithms
2009-11-13 - English

Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients. Results from the HERMES study
2009-11-13 - English

RELATIONS BETWEEN CARDIOVASCULAR RISK ESTIMATES AND SUBCLINICAL ATHEROSCLEROSIS IN NAIVE HIV PATIENTS. RESULTS FROM THE HERMES STUDY
Giuseppe Vittorio L. De Socio, Canio Martinelli, Elena Ricci, Giancarlo Orofino, Laura Valsecchi, Paola Vitiello, Laura Martinelli, Tiziana...(more)

Prevalence and relevance of drug-drug interactions in the Swiss HIV cohort study
2009-11-13 - English

Immuno-virological response to triple NRTI and boosted PI in treatment-naïve HIV-2-infected patients - The ACHIEV2E Collaboration Study Group
2009-11-13 - English

Inflammatory biomarkers predict cardiovascular events in HIV positive patients receiving cART: a case control study
2009-11-13 - English

The role of serum biomarkers in determining the cardiovascular risk in HIV-infected patients on cART

Both once-daily saquinavir/ritonavir and atazanavir/ritonavir, when combined with tenofovir/emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reduction in glomerular filtration over 48 weeks: the BASIC trial
2009-11-13 - English

Body composition changes in treatment-naive patients treated with boosted PIs plus TDF/FTC: results from the CASTLE study through 96 weeks
2009-11-13 - English

Sexual Health for Persons Living with HIV
2009-11-14 - English

HCV/HIV Co-infection: Safety and Regulatory Issues for Drug Development
2009-11-14 - English

The Threat of Drug Resistant Tuberculosis in Eastern Europe
2009-11-14 - English

Problems of MDR-TB in HIV-infected pateints.
MDR-TB in Russia